Effective January 1st, Genentech will be updating the co-pay program benefit period. The program will be moving from a 12-month benefit to a calendar year benefit (January to December).
Patient benefit will automatically renew annually for all patients enrolled in the program on January 1st.
For more information, please call the Help Desk at 800-636-0316.
The information contained in this section of the site is intended for US specialty pharmacy representatives only. Click "OK" if you are a specialty pharmacy representative.
You pay as little as $5 per prescription for Evrysdi if you qualify for the Evrysdi Co-pay Program. Eligible commercially insured patients who are prescribed Evrysdi for an FDA-approved use can receive up to $25,000 per calendar year for drug costs.
Have a temporary reference number and want to return to the confirmation screen?
Enter your information here:
Evrysdi is a prescription medicine used to treat spinal muscular atrophy (SMA) in children and adults.
These are not all of the possible side effects of Evrysdi. For more information on the risk and benefits profile of Evrysdi, ask your healthcare provider or pharmacist.
You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Please see accompanying full Prescribing Information for additional Important Safety Information.